Massive Bio launches hub for precision oncology data network

New York City-based Massive Bio has established a hub for facilitating partnerships between vendors and provider clinical research teams, part of its efforts to create the largest oncology clinical trial network.

The hub will evaluate potential partners, including provider networks, pharmaceutical companies and contract research organizations, and form strategic alliances between them. The formation of these partnerships within the network will accelerate clinical research and trials and, ultimately, drug discovery for precision oncology treatments.

The partners will also benefit from Massive Bio's artificial intelligence-powered clinical trial identification and enrollment. The technology automatically combs patient databases to find those most suitable for each trial, not only speeding up the enrollment process, but also ensuring higher than average retention rates, according to Selin Kurnaz, PhD, co-founder and CEO of Massive Bio.

More articles on innovation:
Oak HC/FT announces 3rd venture capital fund totaling $800M
How SCL Health's Peter Kung promotes innovation among staff
OSF HealthCare's investment arm launches 2nd $75M fund

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers